Oral nutritional supplements (ONS) are increasingly being used in the community in a diverse range of patients suffering from diseases (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, human immunodeficiency virus and acquired immune deficiency syndrome, and liver and gastrointestinal disease) that may impair appetite and food intake (Plata-Salaman, 1996; Tisdale, 1997) , and ultimately affect body weight and nutritional status (Schurch & Scrimshaw, 1987; James & Ralph, 1992; Ramsey et al. 1992; Elia & Lunn, 1996) . There are a huge number of ONS (liquid sip-feeds, bars, puddings, powders) in use in clinical practice. They are typically macronutrient supplements (carbohydrate, protein, fat), which may also contain vitamins, minerals and trace elements. Many ONS are prescribable, and indeed there has been a notable increase in the number of prescription items for enteral nutrition in recent years (British National Formulary Section 9.4.2; Department of Health, 1991-7) , mostly attributable to ONS (Department of Health, 1991-7) . The cost implications to the National Health Service are significant, with total expenditure on ONS exceeding £1·5 million in 1997. Also, ONS are now being used more commonly in the community than in hospitals. However, it is startling to find that there is little agreement about the value of such supplements in patients with different diseases or conditions living in the community. Furthermore, as a consequence there are no generally agreed recommendations for their use. Before such recommendations can be made, fundamental questions about the effects of oral supplements on body weight and/or composition, habitual food intake and, most importantly, body function in different clinical situations need to be systematically addressed.
In particular, one outstanding issue is whether the energy consumed as a supplement merely suppresses appetite and food intake, replacing the energy habitually taken from food, and so failing to substantially increase total energy intake. If there is no increase in total energy intake, then improvements in body weight, composition and function may not follow. If the supplement replaces normal food intake, then the cost of the supplement prescription is effectively 'purchasing' food. In contrast, if the energy of the supplement is additional to that from habitual food intake, then improvements in body weight, and possibly function, may follow. The extent to which artificial nutrition (Stratton & Elia, 1999b) , and in particular ONS, suppresses appetite and food intake may depend on the consistency (solid v. liquid; Pliner, 1973; Malagelada et al. 1979; Kissileff, 1985) or the composition (macronutrient content, energy density; Stubbs, 1992; Poppit & Prentice, 1996; Stubbs et al. 1998) of the supplement and the times and frequency of consumption.
As the available information on the effects of use of ONS in the community setting had not previously been amalgamated to address the issues mentioned earlier, a critical systematic review of studies conducted to assess the effects of ONS in different groups of patients living in the community was undertaken (Stratton & Elia, 1999a 
Review methodology
The systematic review was conducted according to explicit and reproducible methodology (Stratton & Elia, 1999a) . The searching methods used to locate relevant studies included computer-based databases (e.g. Medline SilverPlatter v.2 (January 1966-June 1998); Bath Information and Data Services (January 1981-June 1998); Cochrane Centre, Oxford), in addition to cross-referencing from reference lists and published papers, reviews and industrial information, discussion with health professionals and academic researchers in specialist areas and consultation with professional bodies (Dickersin et al. 1994; McManus et al. 1998) . Inclusion criteria for studies were established (Table 1) , specifying the population (e.g. patients), the intervention (e.g. types of ONS) and the outcome measures (e.g. body weight, function). All studies were independently categorized and coded according to study design by two investigators (Table 2 ). Due to the scarcity of randomized controlled trials in some groups, particularly in children with disease-associated growth failure (in whom placebo groups would not be ethically feasible), non-randomized trials were also included in the review.
Information on the number of patients studied (both supplemented and unsupplemented), their initial nutritional status, their disease or clinical condition, the duration of ONS and the type, composition and quantity of supplement given was gathered for each of the trials reviewed. A record was also made of a number of outcome measures following ONS. These outcome measures included: body weight and structure; information on changes in body weight or BMI, lean body mass, fat mass, arm anthropometry and indices of growth were recorded; total energy intake and food intake; changes in total energy intake observed during studies were recorded and quantified when the data was available. An estimation of the percentage of supplement energy that was additive to food energy was calculated where possible (Stratton & Elia, 1999a) ; body function; general functional outcomes, such as quality of life, well-being and hand-grip strength were noted in addition to disease-specific outcomes (e.g. respiratory muscle strength in patients with COPD).
Summary of studies reviewed

Population
Eight-four trials (2570 patients) were included in the systematic review to assess the effects of ONS consumption in disease-specific groups living in the community. Studies were grouped according to disease or condition as follows: COPD (fourteen trials), Crohn's disease (nine trials), cystic fibrosis (eleven trials), elderly (twelve trials), human immunodeficiency virus and acquired immune deficiency syndrome (fifteen trials); liver disease (two trials), malignancy (fifteen trials); other conditions (six trials). All supplementation studies were carried out in the community setting: 83 % (n 70) were conducted in patients living at home and 4 % (n 3) in residential homes; 8 % (n 7) were in patients who started in hospital and continued as outpatients; 5 % (n 4) were partly or totally conducted in a research centre. 
4.
Use of oral nutritional supplements: prescribable or non-prescribable; macronutrient supplements (CHO, fat, protein) in the form of commercial sip feeds, bars, puddings, powders reconstituted as drinks or added to food or drink; home-made supplements. Studies using nutritional supplements containing only branched-chain amino acids or micronutrients were excluded Non-pregnant subjects of all ages All studies must be 'community based': studies involving outpatients living at home or in a research centre; patients in long-term residential care. Studies in which supplementation was started in hospital and continued at home after discharge were included. Studies in developing countries were excluded Randomized and non-randomized designs CHO, carbohydrate. Forty-five trials (54 % of the total; n 1728 patients) were randomized and thirty-nine trials (n 842 patients) were not (see Table 3 ). Overall, studies tended to include small numbers of patients, as illustrated in Fig 1. Furthermore, only three of the eight-four trials reported the use of power calculations to indicate the necessary sample size needed to show a treatment effect (Evans et al. 1987; Chlebowski et al. 1993; Keele et al. 1997) . In some cases study sample size was considered to be insufficient to detect significant changes in weight and other outcome measures (type II error). For example, simple power statistics (at 80 % power; Altman, 1991) , suggest that more than 120 subjects would be needed to detect a weight change of 1·5 (SD 3) kg.
Intervention
Liquid ONS were used (either commercial sip-feeds or powders reconstituted to form a liquid supplement) in more than 80 % (n 67) of the studies reviewed. A minority of studies appeared to use solid supplements (bars, puddings; n 2), powders added to normal food and drink (n 1) and home-made (non-commercial) supplements (n 4). In ten studies neither the name nor the type of supplement used was documented. The energy density of supplements varied considerably (3·25-16·0 kJ/ml), as did their composition (protein-hydrolysate formulas, elemental formulas, medium-chain triacylglycerol-enriched, branched-chain amino acid-enriched and 'immuno-modulatory' formulas with extra arginine, n-3 fatty acids and nucleic acids). Standard formulas (approximately 15 % energy as protein, 35 % energy as fat and 50 % energy as carbohydrate) were also commonly used. The amounts prescribed ranged from < 0·42 MJ/d to > 10·5 MJ/d, for periods ranging from 1 week to over 2 years. Some studies (n 19) provided 'recommendations' to patients about when to consume the ONS, although it appeared that patient compliance with this timing was not checked. Suggested times varied considerably, and included between meals (Lipschitz et al. 1985; Woo et al. 1994; Volkert et al. 1996) , with meals (Breslow et al. 1993) , early in the morning (Cederholm & Hellstrom, 1995) , during the afternoon (Sondel et al. 1987) or in the evening (Fiatarone et al. 1994) , with the aim to maximally increase total energy intake. Conclusions about the best time and frequency of ONS consumption in different disease groups could not be reached from the studies reviewed, in particular due to a lack of formal comparisons of these different schedules. 
Outcome measures
The systematic review set out to answer a number of questions about the effects of ONS on a variety of outcome measures in patients in the community, some of which will be addressed briefly.
What effect do oral nutritional supplements have on body structure and weight? Following ONS, weight gain varied considerably and depended on the duration and amount of supplementation, and the disease status of patients. Mean percentage weight change in supplemented patients compared with unsupplemented control patients could be calculated in twenty-two randomized controlled studies of adults (duration of ONS 10 d-1 year, n 900 patients; Douglass et al. 1978; Foster et al. 1980; Elkort et al. 1981; Simko, 1983; Lewis et al. 1987; Norregaard et al. 1987; Efthimiou et al. 1988; Knowles et al. 1988; Arnold & Richter, 1989; Donahoe et al. 1989; Otte et al. 1989; Fuenzalida et al. 1990; Nayel et al. 1992; Rogers et al. 1992; Hirsch et al. 1993; Fiatarone et al. 1994; Woo et al. 1994; Gray-Donald et al. 1995; Volkert et al. 1996; Jensen & Hessov, 1997; Keele et al. 1997; Rabeneck et al. 1998) . The mean percentage weight change of patients receiving ONS (2·93 %) was greater than that of the unsupplemented control patients (1·15 %, mean difference 1·77, range −2·69 to 9·2 %; weighted for the number of subjects in each category). Furthermore, of these studies, those in which supplemented patients had a mean BMI < 20 kg/m 2 (eleven studies) were associated with a greater percentage weight change (4·7 % of the body weight) than in those in which patients had a mean BMI > 20 kg/m 2 (2·4 % of the body weight; five studies). Similarly, the non-randomized studies showed that weight gain was greater in those patients with a mean BMI < 20 kg/m 2 (mean 2·1 kg) than in those with a mean BMI > 20 kg/m 2 (mean 1 kg). It was also possible to summarize the effects of ONS on percentage weight change according to specific disease groupings. Fig. 2 shows the results expressed as 95 % CI. Supplemented patients had greater weight gain (or less weight loss) than unsupplemented patients in all disease categories, except for liver disease. Indeed, the greatest difference in weight change between supplemented (ONS for 1-4 months; + 4·4 %) and unsupplemented patients (−0·25 %) occurred in those with COPD. This group of patients had a lower BMI than that of the other disease categories.
The impact of ONS on growth-retarded children (aged 4 months-19 years; diagnoses: cystic fibrosis, Crohn's disease, failure to thrive; n 220) could be evaluated in eleven of twelve studies reviewed. All studies showed improvements in growth, although in only seven trials were statistically significant improvements in weight or height centiles demonstrated (Allan et al. 1973; Berry et al. 1975; Yassa et al. 1978; Kirschner et al. 1981; Parsons et al. 1983; Shepherd et al. 1983; Skypala et al. 1998 ). Significant increases in muscle and fat mass were reported in approximately 50 % (sixteen of thirty-seven) of studies that made measurements of body composition after ONS, but there was insufficient information to form conclusions about the effects of ONS on body composition in different disease groups.
Ultimately, it should be acknowledged that a large number of the trials reviewed did not document the nutritional status of patients (n 40), ten studies failed to document the effect of ONS on body weight and more than 50 % of studies did not attempt to measure body composition (and most of those that did only used upper-arm anthropometry). Furthermore, in most studies the presence or absence of oedema was not recorded, despite its potential to affect weight change.
What effect do oral nutritional supplements have on total energy intake, spontaneous food intake and appetite? Of the twenty-seven randomized controlled trials that assessed total energy intake, all showed an increase during ONS. The increase was evaluated to be statistically significant in only eighteen studies: surgery (Jensen & Hessov, 1997; Keele et al. 1997) ; liver disease (Simko, 1983; Hirsch et al. 1993) ; cancer (Evans et al. 1987; Ovesen & Allingstrup, 1992) ; the elderly (Meredith et al. 1992; Fiatarone et al. 1994; Woo et al. 1994) ; cystic fibrosis (Sondel et al. 1987 ) and Crohn's disease (Harries et al. 1983) ; COPD (Lewis et al. 1987; Norregaard et al. 1987; Efthimiou et al. 1988; Knowles et al. 1988; Fuenzalida et al. 1990; Rogers et al. 1992) ; other diseases (Kuhlmann et al. 1997) . Although fourteen of sixteen non-randomized trials that assessed total energy intake showed an increase, in only seven was this increase statistically significant (Lynch et al. 1983; Parsons et al. 1983; Stauffer et al. 1986; Welch et al. 1991; Gray-Donald et al. 1994; Tolia, 1995; Skypala et al. 1998) . The extent to which the energy from the ONS replaced or added to that from food could be assessed in seventeen trials, the results of which are summarized graphically in Fig. 3 (for details of methodology, see Stratton & Elia, 1999a) . Overall, the supplement energy was largely additional to that taken orally (mean increase in energy intake equivalent to 67 % of the energy of the ONS consumed), but this contribution varied considerably according to the disease state and the BMI of patients (e.g. 79 % of the ONS energy in those patients with a BMI < 20 kg/m 2 (eight studies); 28 % of the ONS energy in those patients with a BMI > 20 kg/m 2 (five studies); Stratton & Elia, 1999a) . None of the studies reviewed formally assessed the impact of ONS on appetite sensations (such as hunger, fullness, desire to eat), although a variety of anecdotal observations were recorded, ranging from a loss of appetite to stimulation of appetite during the supplementation period.
However, in many studies there was limited information about the quantity, composition and type of ONS consumed. For example, in only 51 % of randomized trials and 36 % of non-randomized trials was it possible to calculate average supplement consumption. In addition, assessments of dietary and ONS intake were often undertaken infrequently (e.g. once per month) and over short periods of time (1-3 d), and so may not have provided an accurate representation of the habitual dietary intake or ONS intake of the patients during the course of the investigation. The majority of studies also made no apparent attempts to estimate the validity of food and supplement intake records (e.g. no checks on the number of supplement cartons used).
What effect do oral nutritional supplements have on body function? Functional changes (assessed in fifty-nine studies) following ONS varied according to the disease or condition of patients, and were typically observed more commonly in those patients with a BMI < 20 kg/m 2 than in those with BMI > 20 kg/m 2 . Functional benefits included improved muscle strength, walking distance and well-being in patients with COPD (Wilson et al. 1986; Efthimiou et al. 1988; Donahoe et al. 1989; Rogers et al. 1992) , improved growth performance in children with cystic fibrosis (Allan et al. 1973; Berry et al. 1975; Yassa et al. 1978; Kirschner et al. 1981; Parsons et al. 1983; Shepherd et al. 1983; Skypala et al. 1998) , reduced falls (Gray-Donald et al. 1995) and increased activities of daily living (Volkert et al. 1996) in the elderly, and improvements in immune function in patients with human immunodeficiency virus (Hellerstein et al. 1994) . It is possible that detriments due to ONS may occur in some overweight patients with certain diseases (e.g. cancer; Elkort et al. 1981; Evans et al. 1987) . Despite the importance of functional outcomes, almost one-third of the studies reviewed appeared to have made no assessments of body function. Similarly, there was a lack of trials that reported the impact of ONS on the quality of life of the patients.
Conclusions
The critical systematic review (Stratton & Elia, 1999a) aimed to comprehensively assess the existing research on the effects of ONS use in diverse patient groups in the community. A number of conclusions can be drawn from the studies reviewed, predominantly in patients with chronic conditions. First, the evidence base would suggest that ONS are associated with demonstrable clinical (including functional) benefits, although the nature and extent of these benefits varies with the underlying chronic condition. Second, improvements in body weight, total energy intake and body function following ONS appear to occur more frequently in individuals with a BMI < 20 kg/m 2 than in individuals with a BMI > 20 kg/m 2 . However, it was difficult to pin-point subgroups of patients within trials who might benefit from ONS, such as those who were losing weight and had a BMI > 20 kg/m 2 . This difficulty was due to a number of limitations in the data such as the collective presentation of results from heterogeneous groups of patients, the use of a variety of types and quantities of ONS and inappropriate study designs (small sample sizes, lack of randomization). What also remains to be determined is whether such clinical benefits could also be achieved by means other than ONS, such as dietetic counselling and food intervention. With the information obtained from the systematic review, recommendations for the use of ONS in clinical practice in the community have been made (Stratton & Elia, 1999a). Finally, there are a number of outstanding areas for research in the future. Controlled comparisons of the efficacy of different forms of therapy to increase dietary intake and improve body weight and function (ONS, behavioural therapy, dietary counselling and combinations of these therapies) are required. Studies also need to be undertaken to establish the type, palatability and size of ONS, as well as the timing and frequency of consumption, that is required to produce optimal short-term and long-term effects on appetite, food intake and clinically-relevant outcome measures, including nutritional status and physical and psycho-social function. Furthermore, studies in the community setting need to be extended to include patients with a range of conditions, including those for which there is little information (e.g. diseases in children, neurological conditions, elderly with pressure sores, dementia, liver and renal disease) and to a variety of settings (nursing homes and alternative care facilities, patient homes and changes in settings, e.g. discharges from hospital to home). Ideally, the research issues mentioned earlier should be investigated by randomized controlled trials involving adequate sample sizes and homogeneous groups of patients (type and stage of specific diseases; different categories of nutritional status and weight loss) so that study findings can more easily and with confidence be incorporated into clinical practice.
